Ketoconazole + Tris-Edta + Phytosphingosine

Verify with FDA CVM →

16 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
16
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Ketoconazole + Tris-Edta + Phytosphingosine

Administration Routes

Auricular (Otic)Unknown

Species Affected

Dog 16

Most Affected Breeds

Retriever - Labrador 4
Shih Tzu 2
Shar Pei 1
Terrier - Boston 1
Chihuahua 1
Dog (unknown) 1
Shepherd Dog - Australian 1
Poodle (unspecified) 1
Setter - English 1
Terrier (unspecified) 1

Most Reported Reactions

Behavioural disorder NOS 4
Lack of efficacy - NOS 3
Vomiting 3
Nasal dryness 3
Vocalisation 2
Pinnal erythema 2
Head shake - ear disorder 2
Uncomfortable 2
Unsteady gait 2
Corneal ulcer 2
Panting 2
Horner's syndrome 2

Outcome Breakdown

Outcome Unknown
6 (37.5%)
Ongoing
6 (37.5%)
Recovered/Normal
4 (25.0%)

Data Summary

Metric Value
Total adverse event reports 16
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 1
Distinct breeds in reports 12
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Ketoconazole + Tris-Edta + Phytosphingosine Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 16 adverse event reports referencing Ketoconazole + Tris-Edta + Phytosphingosine, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Ketoconazole + Tris-Edta + Phytosphingosine. Reported administration routes include Auricular (Otic), Unknown. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ketoconazole + Tris-Edta + Phytosphingosine reports are Dog (16 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (4), Shih Tzu (2), Shar Pei (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ketoconazole + Tris-Edta + Phytosphingosine are Behavioural disorder NOS (4), Lack of efficacy - NOS (3), Vomiting (3), Nasal dryness (3). Of the 16 reports with a coded outcome, Outcome Unknown is the leading category at 37.5%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ketoconazole + Tris-Edta + Phytosphingosine.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial